1. Home
  2. NRXS

as of 02-17-2026 3:35pm EST

$5.34
+$0.42
+8.66%
Stocks Nasdaq

Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).

Founded: 2011 Country:
N/A
Employees: N/A City: CARMEL
Market Cap: 46.3M IPO Year: N/A
Target Price: $8.00 AVG Volume (30 days): 83.5K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $1.33 - $6.20 Next Earning Date: 01-01-0001
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): 31.05% Revenue Growth (next year): 146.31%
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

AI-Powered NRXS Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 2 days ago

AI Recommendation

hold
Model Accuracy: 73.00%
73.00%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of Neuraxis Inc. (NRXS)

Aharon Gil

Director

Buy
NRXS Dec 23, 2025

Avg Cost/Share

$3.52

Shares

286,138

Total Value

$1,007,205.76

Owned After

286,138

SEC Form 4

Latest Neuraxis Inc. News

NRXS Breaking Stock News: Dive into NRXS Ticker-Specific Updates for Smart Investing

All NRXS News

Share on Social Networks: